Yale Cancer Center welcomed members of the External Scientific Advisory Board (ESAB) to campus on Tuesday and Wednesday of this week for their annual meeting. The Board listened to presentations from the leadership of the cancer center research programs and shared resources and will provide recommendations following a thorough review of the programs. In addition, we are currently undergoing a strategic review of the Cancer Center Core Grant Renewal, due for submission to the National Cancer Institute.
Frederick R. Appelbaum, MD, Fred Hutchinson Cancer Research Center
Colin Begg, PhD, Memorial Sloan-Kettering Cancer Center
Deborah J. Bowen, PhD, Boston University
Robert DuWors, MBA, Jonsson Comprehensive Cancer Center
Timothy J. Eberlein, MD, The Alvin J. Siteman Cancer Center
Eli Gilboa, PhD, Sylvester Cancer Center
Mark A. Israel, MD, Norris Cotton Cancer Center
Linda Jacobs, PhD, RN, Abramson Cancer Center
Richard Jove, PhD, City of Hope Comprehensive Cancer Center
Thomas A. Sellers, PhD, H. Lee Moffit Cancer Center and Research Institute
Jeffrey Settleman, PhD, Massachusetts General Hospital Cancer Center
Lyndsay Harris Awarded BCRF Grant
Dr. Lyndsay Harris has received a grant from the Breast Cancer Research Foundation to better understand the mechanisms of response and resistance to paclitaxel and trastuzumab to treat breast cancer. The funded research project builds on existing research on cohorts of patients treated with trastuzumab and paclitaxel to define markers of response to these therapies. In addition, Dr. Harris and her team will evaluate the host response to these agents. They will ultimately develop a model that integrates tumor and host features of therapeutic benefit to provide a 'fingerprint' for patients and their providers, which will allow them to optimize therapeutic choices.
Beth Jones Presents to the President's Cancer Panel
Beth Jones, PhD was one of 12 invitees to present testimony to the President's Cancer Panel in Los Angeles, California on October 27, 2009. Citing her expertise and research with respect to racial/ethnic differences in breast cancer, Dr. Jones was invited to present a paper entitled, The Changing US Population and Breast Cancer Disparities: Lessons Learned from the Study of African American Women. The President's Cancer Panel was established by The National Cancer Act of 1971 and is charged with overseeing the National Cancer Program (NCP). Information gathered from their meetings is used to monitor the development and execution of the NCP and to submit annual reports to the President.
Learn More >>
Hari Deshpande Receives Billing Compliance Award
Each year, the Yale Medical Group Compliance Office presents a compliance award to individuals who demonstrate diligence in their medical billing compliance efforts. Hari Desphande, MD, Assistant Professor of Medical Oncology received the honor for 2009. Dr. Deshpande has served as the Medical Oncology Billing Compliance Leader since 2005 and has been a valuable resource to faculty and the Compliance Department with billing and audit issues.
Learn More >>
Operations are in full swing in Radiation Oncology, which saw its first patient on Monday, October 26th. Regular clinic appointments began this week in the lower level, and have proceeded as planned. Parking is also running smoothly through the valet service for radiation oncology patients. Operations planning is currently being finalized for the Women's Health Center on the first floor, which is scheduled to open next month.
The Occupancy team is currently installing equipment and furniture in anticipation of a December occupancy for Diagnostic Radiology on the second floor.
The Education and Orientation team is holding multiple employee sessions every week. Participant feedback has been very positive, particularly on the patient and family discussion panels that are included in every session.
Hodgkin's Lymphoma of the Breast.
Hoimes CJ, Selbst MK, Shafi NQ, Rose MG, Rosado MF.
J Clin Oncol. 2009 Nov 2.
Read More >>
Comparison of Neurocognitive Functioning in Children Previously Randomly Assigned to Intrathecal Methotrexate Compared With Triple Intrathecal Therapy for the Treatment of Childhood Acute Lymphoblastic Leukemia.